CD226 and neoplasm: The expanding DNTs in vivo acquired an anti-tumor phenotype with the NK cell marker NKG2D, DNAM-1, which mediated the cytotoxicity response targeting cancer cells by secreting cytotoxic cytokines such as IFNγ and soluble TRAIL (sTRAIL) [34].